

Your reference
Our reference
Date

October 14, 2025

Changes to Franklin Templeton Investment Funds (“FTIF”) and the Underlying Funds (as defined below)

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

Zurich Assurance Ltd
(a company incorporated in England and Wales with limited liability)

We accept full responsibility for the accuracy of the content of this document. Unless otherwise specified herein, capitalized terms used in this letter shall have the meanings assigned to such terms in the Explanatory Memorandum of FTIF dated August 2025, as amended from time to time (the “Explanatory Memorandum”).

Zurich Life Insurance (Hong Kong) Limited
(a company incorporated in Hong Kong with limited liability)

Dear valued customer,

25-26/F, One Island East
18 Westlands Road
Island East, Hong Kong

We are writing to let you know about the changes to FTIF and the Underlying Funds. You have invested in at least one of the investment choices corresponding to the Underlying Funds, which are listed in the “Which investment choices are affected?” table below under the column “Name and code of the investment choice”.

Which investment choices are affected?

Website: www.zurich.com.hk

Name and code of the investment choice (Individually, the “Investment Choice”; collectively, the “Investment Choices”)	Name of the corresponding underlying fund (Individually, the “Underlying Fund”; collectively, the “Underlying Funds”)	Applicable scheme (Collectively, the “Schemes”)
Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund (Code: PTUSD)	Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund	• Magnitude • Matterhorn • Swiss Elite
Franklin Templeton Investment Funds - Franklin Innovation Fund (Code: SMUSD)	Franklin Templeton Investment Funds - Franklin Innovation fund	
Franklin Templeton Investment Funds - Franklin Technology Fund (Code: NSUSD)	Franklin Templeton Investment Funds - Franklin Technology Fund	
Franklin Templeton Investment Funds - Franklin U.S. Opportunities Fund (Code: NTUSD)	Franklin Templeton Investment Funds - Franklin U.S. Opportunities Fund	

What is happening?

We have been notified by Franklin Templeton Investments (Asia) Limited, as the Hong Kong representative of FTIF (the “**Hong Kong Representative**”), of the changes set out below.

Changes to the SFDR pre-contractual disclosures of the Underlying Funds

The board of directors of FTIF has decided to make amendments to the SFDR pre-contractual disclosures of the Underlying Funds, effective September 22, 2025 (the “**Effective Date**”). Accordingly, the paragraph under the section titled “What investment strategy does this financial product follow?” relating to ESG exclusions in the SFDR pre-contractual disclosures of the Underlying Funds will be revised as follows:

Summary of Change(s)
Removal of the following exclusion: ○ <i>Generate more than 10% of revenue from the production and/or distribution of weapons;</i> Update to the following exclusion: ○ <i>Manufacture tobacco or tobacco products; or those that derive more than 5% of their revenue from such products;</i>

On or around the Effective Date, the updated SFDR pre-contractual disclosures for the Underlying Funds are available for download from the Hong Kong Representative’s website at https://franklintempletonprod.widen.net/s/jqdp5bk5xt/ftif-sfdr-pre-contractual-disclosure-annexes_hk_en¹ (English version) and https://franklintempletonprod.widen.net/s/hv85nxn6tb/ftifsfdr-pre-contractual-disclosure-annexes_hk_cn¹ (Traditional Chinese version).

As confirmed by the Hong Kong Representative, the above changes will have no material impact on the features and risks applicable to the Underlying Funds. They will also have no material impact on the operation and/or manner in which the Underlying Funds are being managed, and there will be no effect on investors. There will be no change in the fee level or cost in managing the Underlying Funds following the implementation of the above changes. It is not expected that the above changes will materially prejudice the rights or interests of investors.

The Explanatory Memorandum will be updated to reflect the above changes in due course. An updated version of the Explanatory Memorandum will be available for download from the Hong Kong Representative’s website at www.franklintempleton.com.hk¹.

What does this mean to you?

If you wish to continue to invest in the Investment Choice(s) after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice(s), you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 2968 2383 or contact us via <https://www.zurich.com.hk/zh-hk/customer-services/contact-us/e-form/life-general> and we will be happy to help.

Yours faithfully,

Zurich Life Insurance (Hong Kong) Limited

¹ This website has not been reviewed by the Securities and Futures Commission.

(a company incorporated in Hong Kong with limited liability)

Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.

有關富蘭克林鄧普頓投資基金（「FTIF」）及該等相關基金（定義見下文）之變更

此乃重要函件，務請您即時垂注。您如對本函件的内容有任何疑問，請尋求專業意見。

我們就此函件所轉載資料的準確性承擔全部責任。除另有規定外，本函件內所用的詞語與FTIF日期為2025年8月的基金說明書（經不時修訂）（「該基金說明書」）所界定者具相同涵義。

親愛的客戶：

我們謹此致函通知您有關FTIF及該等相關基金的變更。您已投資於該等相關基金相應的至少一個投資選項，其列於下表「受影響的投資選項」中「投資選項的名稱及代碼」一欄。

受影響的投資選項

投資選項（各稱為「該投資選項」，統稱為「該等投資選項」）的名稱及代碼	相應的相關基金（各稱為「該相關基金」，統稱為「該等相關基金」）名稱	適用計劃（統稱「計劃」）
富蘭克林鄧普頓投資基金 - 富蘭克林生物科技新領域基金（代碼：PTUSD）	富蘭克林鄧普頓投資基金 - 富蘭克林生物科技新領域基金	- 瑞豐投資計劃 - 瑞承投資計劃 - 瑞翔投資計劃
富蘭克林鄧普頓投資基金 - 富蘭克林創新領域基金（代碼：SMUSD）	富蘭克林鄧普頓投資基金 - 富蘭克林創新領域基金	
富蘭克林鄧普頓投資基金 - 富蘭克林科技基金（代碼：NSUSD）	富蘭克林鄧普頓投資基金 - 富蘭克林科技基金	
富蘭克林鄧普頓投資基金 - 富蘭克林美國機會基金（代碼：NTUSD）	富蘭克林鄧普頓投資基金 - 富蘭克林美國機會基金	

修訂事項

FTIF的香港代表富蘭克林鄧普頓投資（亞洲）有限公司（「該香港代表」）已通知我們以下變更。

該等相關基金的SFDR合約前披露變更

FTIF的董事局已決定對該等相關基金的SFDR合約前披露作出修訂，自2025年9月22日（「生效日期」）起生效。因此，該等相關基金的SFDR合約前披露中標題為「此金融產品遵循什麼投資策略？」一節下有關ESG排除的段落將修訂如下：

變更概述
刪除以下排除情況： 10% 以上的收入來自武器生產及／或分銷； 更新以下排除情況： - 製造煙草或煙草製品或從此類產品中獲得超過5% 的收入；

於生效日期或前後，該等相關基金基金的經更新 SFDR 合約前披露可於該香港代表的網站下載 https://franklintempletonprod.widen.net/s/jqdp5bk5xt/ftif-sfdr-pre-contractual-disclosure-annexes_hk_en¹（英文版本）及 https://franklintempletonprod.widen.net/s/hv85nxn6tb/ftif-sfdr-pre-contractual-disclosure-annexes_hk_cn¹（繁體中文版本）。

¹ 本網站未經證券及期貨事務監察委員會審核。

該香港代表已確認，上述變更不會對適用於該等相關基金的特徵及風險產生重大影響。其亦將不會對該等相關基金的運營及 / 或管理方式產生重大影響，並且不會對投資者造成影響。在實施上述變更後，該等相關基金的費用水平或管理該等相關基金的成本將不會發生變化。預計上述變更不會對投資者的權利或利益造成重大損害。

該基金說明書將適時更新，以反映上述變更。該基金說明書的更新版本可於該香港代表網站 www.franklintempleton.com.hk¹ 下載，並適時於該香港代表辦事處提供。

對您產生的影響

如您在考慮上述變更後仍希望繼續投資於該等投資選項，則無需就此修訂作出任何行動。倘若您不欲繼續投資於該等投資選項，可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選項的指示，費用全免。

我們建議您首先諮詢您的持牌保險中介人，以取得其他投資選項的建議。有關本公司投資選項（包括費用及收費，以及其相關風險因素）的詳情，請參閱相關計劃的產品介紹冊及相關基金的銷售文件，本公司會應要求提供上述銷售文件。

如您對本函件或投資選項中的投資有任何疑問，請聯絡您的持牌保險中介人。您亦可致電+852 2968 2383或經由 <https://www.zurich.com.hk/zh-hk/customer-services/contact-us/e-form/life-general> 聯絡我們，我們將樂意為您效勞。

蘇黎世人壽保險（香港）有限公司
（於香港註冊成立之有限公司）
2025年10月14日

註：投資涉及風險，您的投資價值及收益可因市場及貨幣波動而下跌，有可能導致您不能取回所有投資款項。